Loading stock data…
$3.23-0.19 (-5.41%)
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.
MacroGenics, Inc. in the Healthcare sector is trading at $3.23 with a market capitalization of $241M. Wall Street consensus targets $8.00 (4 analysts), implying a +147.3% move over the next 12 months. The stock is currently 36% below its 52-week high of $5.08, remaining 3.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $32.83M↑ | $20.77M↓ | $41.23M↓ | $72.84M↑ | $6.87M |
| Gross Profit | — | $11.24M↓ | $31.11M↓ | $61.25M↑ | $13.34M |
| Operating Income | -$13.85M↑ | -$33.44M↓ | -$12.10M↓ | $18.64M↑ | -$43.22M |
| Net Income | $19.52M↑ | -$36.77M↓ | -$14.15M↓ | $16.82M↑ | -$36.25M |
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a...